2020
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry 2020, 19: 15-33. PMID: 31922684, PMCID: PMC6953551, DOI: 10.1002/wps.20693.Peer-Reviewed Original ResearchDopamine systemAberrant dopamine signallingStriatal dopamine synthesisNovel pharmacological therapiesPathophysiology of schizophreniaEnvironmental risk factorsPharmacological therapyGlutamatergic dysfunctionDopaminergic functionRisk factorsGlutamate systemDopamine synthesisGenetic risk variantsPreclinical studiesPsychotic symptomsDopamine functionNew treatmentsNeural circuitsDopamine signalingNeuronal signalingSchizophreniaConsistent findingRisk variantsSymptomsGlutamate
1996
Noradrenergic mechanisms in stress and anxiety: II. Clinical studies
Bremner J, Krystal J, Southwick S, Charney D. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 1996, 23: 39-51. PMID: 8723134, DOI: 10.1002/(sici)1098-2396(199605)23:1<39::aid-syn5>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderBlood pressureNoradrenergic functionHeart rateNoradrenergic systemClinical studiesAdrenergic receptorsPanic disorderAnxiety disordersGrowth hormone responseMeasurement of norepinephrineNorepinephrine responseNoradrenergic mechanismsBaseline norepinephrineNoradrenergic responsivenessPharmacological challengeCatecholaminergic functionHormone responseTraumatic remindersPatientsAcute stressorStress disorderNorepinephrineBaseline measuresConsistent finding